Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment.

Abstract

Since its discovery in 1951, chlorpromazine (CPZ) has been one of the most widely used antipsychotic medications for treating schizophrenia and other psychiatric disorders. In addition to its antipsychotic effect, many studies in the last several decades have found that CPZ has a potent antitumorigenic effect. These studies have shown that CPZ affects a number of molecular oncogenic targets through multiple pathways, including the regulation of cell cycle, cancer growth and metastasis, chemo-resistance and stemness of cancer cells. Here we review studies on molecular mechanisms of CPZ's action on key proteins involved in cancer, including p53, YAP, Ras protein, ion channels, and MAPKs. We discuss common and overlapping signaling pathways of CPZ's action, its cancer-type specificity, antitumorigenic effects of CPZ reported in animal models and population studies on the rate of cancer in psychiatric patients. We also discuss the potential benefits and limitations of repurposing CPZ for cancer treatment.

• Authors: Pareesa Kamgar-Dayhoff, Tinatin I Brelidze
• Journal: Oncotarget (Oncotarget) Vol. 12 Issue 14 Pg. 1406-1426 (Jul 06 2021) ISSN: 1949-2553 [Electronic] United States
• PMID: 34262651 (Publication Type: Journal Article)
• Copyright: Copyright: © 2021 Kamgar-Dayhoff and Brelidze.